Suppr超能文献

Rigicon Infla10® 可充气阴茎假体的初步安全性结果。

Initial safety outcomes for the Rigicon Infla10® inflatable penile prosthesis.

机构信息

Department of Urology, Institute for Urologic Excellence, La Quinta, CA, USA.

Department of Urology, Mayo Clinic, Rochester, MN, USA.

出版信息

BJU Int. 2023 Jun;131(6):729-733. doi: 10.1111/bju.15960. Epub 2023 Mar 6.

Abstract

OBJECTIVE

To analyse data from patient information forms (PIFs) submitted to the manufacturer of a new three-piece inflatable penile prosthesis (IPP), the Rigicon Infla10®, to summarize early outcomes.

METHODS

A retrospective review of PIFs from 319 patients implanted with the IPP between 6 January 2019 and 31 December 2021 was performed to assess device durability and rates of reoperation for infection, mechanical failure or medical reasons.

RESULTS

The mean ± sd (range) follow-up was 21.2 ± 11 (5-36) months and the mean ± sd patient age was 58.5 ± 8.7 years. Of the total, 4.4% of devices required removal or revision. Complications included mechanical failure (2.5%) and component migration (0.7%). No infections were observed in this series. One patient (0.4%) required revision for inadequate straightening of Peyronie's disease. Three patients (0.9%) requested device removal because of dissatisfaction. A total of 95.6% of the Rigicon Infla10 devices were free from explant or revision 21 months after the original implant date. Kaplan-Meier analysis showed the rates of cumulative survival of the device at 12, 24, 36 months were 95.6%, 94.7% and 93.7%, respectively.

CONCLUSIONS

The vast majority of the early Rigicon Infla10 IPPs implanted prior to January 2022 were included in this retrospective analysis of volunteered PIFs. These early results demonstrate initial durability from reoperation equivalent to that of other contemporary devices.

摘要

目的

分析提交给新型三件式可充气阴茎假体(IPP)制造商的患者信息表(PIF)中的数据,总结早期结果。

方法

对 2019 年 1 月 6 日至 2021 年 12 月 31 日期间植入 IPP 的 319 名患者的 PIF 进行回顾性分析,以评估设备的耐用性和因感染、机械故障或医疗原因再次手术的发生率。

结果

平均随访时间为 21.2±11(5-36)个月,平均年龄为 58.5±8.7 岁。在所有患者中,有 4.4%的患者需要取出或修改设备。并发症包括机械故障(2.5%)和部件迁移(0.7%)。本系列中未观察到感染。1 名患者(0.4%)因佩罗尼病矫正不足需要修正。3 名患者(0.9%)因不满意而要求取出设备。原始植入日期后 21 个月,有 95.6%的 Rigicon Infla10 设备无需取出或修正。Kaplan-Meier 分析显示,设备的累积存活率在 12、24、36 个月时分别为 95.6%、94.7%和 93.7%。

结论

在这项回顾性分析中,纳入了 2022 年 1 月之前植入的大量早期 Rigicon Infla10 IPP,自愿提供的 PIF 数据。这些早期结果表明,与其他当代设备相比,该设备的初始耐用性相当。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验